Q2 2024 Hansa Biopharma AB Earnings Call Transcript

Jul 18, 2024 / 12:00PM GMT
Operator

Hello, everyone, and welcome to the Hansa Biopharma Q2 2024 conference call. Today's call is being recorded. (Operator Instructions) I'll now hand the call over to CEO, Soren Tulstrup. Please begin.

Soeren Tulstrup - Hansa Biopharma AB - President, Chief Executive Officer

Thank you, operator. Good afternoon, good morning, and welcome, to the Hansa Biopharma conference call to review the first half and Q2 results for 2024. I'm Soren Tulstrup, President and CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; Matt Shaulis, Chief Commercial Officer and US President; Hitto Kaufmann, Chief R&D Officer. Please turn to slide 2.

These allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation and you should, therefore apply appropriate caution.

Please turn to slide 3 and an overview of today's agenda. They will discuss the progress we made during the first half of 2024 and review our near term authorities. The presentations should take roughly 15 to 20

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot